Source comparison
Peptides for Athletic Recovery Research: Comparison
BPC-157 Angiogenesis promotion, collagen synthesis upregulation VEGFR2, growth factor signaling 200–500 mcg daily (animal models; human equivalence not established) Strong pre-clinical evidence across multiple tissue types; no Phase III human trials 28 days at
This comparison does not assign a generated winner or score.
- BPC-157
- Angiogenesis promotion, collagen synthesis upregulation
- VEGFR2, growth factor signaling
- 200–500 mcg daily (animal models; human equivalence not established)
- Strong pre-clinical evidence across multiple tissue types; no Phase III human trials
- 28 days at 2–8°C
- Best-documented peptide for soft tissue repair; mechanism well-characterized; lacks regulatory approval for human therapeutic use
- TB-500
- Actin binding, cell migration facilitation, MMP upregulation
- Actin monomers, intracellular signaling
- 2–5 mg weekly (veterinary data; human dosing extrapolated)
- Extensive veterinary evidence; limited human clinical data
- 21 days at 2–8°C (shorter due to larger molecular size)
- Strong mechanistic rationale and real-world veterinary outcomes; translation to human athletics requires caution; sensitive to temperature
- Ipamorelin
- Selective growth hormone secretagogue
- Ghrelin receptor (GHSR1a) in pituitary
- 200–300 mcg daily in divided doses
- Moderate human clinical evidence in GH deficiency and aging populations; no sports-specific trials
- Cleanest GH secretagogue profile (no cortisol/prolactin spike); indirect recovery benefits via IGF-1 pathway; well-tolerated in human studies
- IGF-1 LR3
- Direct IGF-1 receptor agonism, satellite cell activation
- IGF-1 receptor on muscle cells
- 40–80 mcg daily (research protocols; human use not approved)
- Strong mechanistic evidence; human studies limited to growth disorders
- 14 days at 2–8°C (highly unstable once reconstituted)
- Potent muscle growth signal; short stability window requires careful handling; regulatory concerns due to anabolic potential
- GHK-Cu
- Copper-dependent collagen remodeling, anti-inflammatory signaling
- TGF-beta pathway, metalloproteinase modulation
- 1–3 mg daily (topical or subcutaneous)
- Moderate clinical evidence in wound healing; primarily dermatological applications
- Well-established in cosmetic medicine; emerging evidence for deeper tissue repair; copper complex requires pH stability